ストックスクリーナーアプリを入手
2.15
5.70%
-0.13
アフターアワーズ：
2.15
前日終値:
$2.28
開ける：
$2.26
24時間の取引高:
1.28M
Relative Volume:
0.74
時価総額：
$128.79M
収益：
-
当期純損益:
$-44.80M
株価収益率:
-2.8667
EPS:
-0.75
ネットキャッシュフロー:
$-30.67M
1週間 パフォーマンス:
-3.15%
1か月 パフォーマンス:
-20.07%
6か月 パフォーマンス:
-56.12%
1年 パフォーマンス:
-42.36%
1日の値動き範囲:
$2.10
$2.26
1週間の範囲:
$2.10
$2.30
52週間の値動き範囲:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
名前
Aldeyra Therapeutics Inc
セクター
電話
781-761-4904
住所
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
2.15 | 132.97M | 0 | -44.80M | -30.67M | -0.75 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-03 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 再開されました | H.C. Wainwright | Buy |
| 2022-04-27 | 再開されました | H.C. Wainwright | Buy |
| 2021-02-08 | 開始されました | H.C. Wainwright | Buy |
| 2020-12-16 | 開始されました | Berenberg | Buy |
| 2020-10-30 | 開始されました | Jefferies | Buy |
| 2020-10-16 | 開始されました | BTIG Research | Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Outperform |
| 2018-12-04 | 開始されました | Citigroup | Buy |
| 2018-09-26 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 開始されました | Janney | Buy |
| 2018-01-26 | 開始されました | Seaport Global Securities | Buy |
| 2016-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2016-07-01 | 開始されました | Stifel | Buy |
| 2015-07-01 | 開始されました | Canaccord Genuity | Buy |
| 2015-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2015-03-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2014-11-18 | 開始されました | H.C. Wainwright | Buy |
| 2014-06-19 | 開始されました | Aegis Capital | Buy |
すべてを表示
Aldeyra Therapeutics Inc (ALDX) 最新ニュース
Trading (ALDX) With Integrated Risk Controls - news.stocktradersdaily.com
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference | ALDX Stock News - GuruFocus
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference - Business Wire
Northern Trust Corp Purchases 16,894 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Acquired by Deutsche Bank AG - Defense World
D. E. Shaw & Co. Inc. Sells 146,198 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs - Defense World
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX): When Will It Breakeven? - Yahoo Finance
HC Wainwright Has Strong Forecast for ALDX FY2029 Earnings - Defense World
Q2 EPS Estimate for Aldeyra Therapeutics Lifted by Analyst - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Raised to “Sell” at StockNews.com - Defense World
Balyasny Asset Management L.P. Acquires New Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics (NASDAQ:ALDX) Given “Buy” Rating at HC Wainwright - Defense World
ALDX: HC Wainwright & Co. Reiterates Buy Rating with $10 Target | ALDX Stock News - GuruFocus
(ALDX) Trading Report - news.stocktradersdaily.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - FinancialContent
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Holdings Lessened by Price T Rowe Associates Inc. MD - Defense World
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire
Aldeyra Therapeutics, Inc. SEC 10-Q Report - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra - Bluefield Daily Telegraph
Hsbc Holdings PLC Acquires Shares of 10,457 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Barclays PLC Has $376,000 Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, - GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical ... - Eagle-Tribune
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm - TradingView
Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early - simplywall.st
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with - GlobeNewswire
Aldeyra makes third run at FDA approval for dry eye drug - The Pharma Letter
Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data - insights.citeline.com
Aldeyra DED phase III hits but reproxalap field goal fumbled - BioWorld MedTech
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Aldeyra Therapeutics, Inc.(ALDX) Investors of a Class Action Lawsuit and Upcoming Deadline - Barchart.com
SHAREHOLDER ALERT: Potential Recovery for Aldeyra Therapeutics, Inc. (ALDX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Aldeyra plots third FDA filing for dry eye disease drug after latest Phase 3 data - Endpoints News
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Ey - GuruFocus
Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial - GuruFocus
Aldeyra (ALDX) Hits Primary Endpoint in Dry Eye Treatment Trial | ALDX Stock News - GuruFocus
Breakthrough in Dry Eye Treatment: Aldeyra's Reproxalap Achieves Significant Phase 3 Results, FDA Filing Next - Stock Titan
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap - Business Wire
ALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, - GlobeNewswire
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
Invesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) - GlobeNewswire
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Renaissance Technologies LLC Purchases 59,700 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Ongoing Securities Investigation - TradingView
Aldeyra Therapeutics Inc (ALDX) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Aldeyra Therapeutics Inc (ALDX) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):